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Survival in first or second remission after lymphocyte-depleted 
transplantation for Philadelphia chromosome-positive CML in first 
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R van der Maazen4 and T de Witte1
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Summary : Allogeneic bone marrow transplantation is the only estab­
lished curative treatment for patients with CML. I-
We studied the outcome of BMT in 38 consecutive CML relapse remains a significant problem. The 4-year
patients in CPI who received transplants depleted of 
lymphocytes using counterflow centrifugation. In all 
patients the conditioning regimen was intensified by the 
addition of anthracyclines. Donors were HLA, MLC- 
identical siblings. Six patients (16%) died within 6 
months. All 37 patients with a follow-up of more than 
0.5 months engrafted and only one (3%) suffered from 
acute GVHD Ss grade 3. Chronic GVHD was evaluable 
in 33 patients and was extensive in six (18%). The pro­
jected 5-year probabilities of hematologic, cytogenetic 
and molecular relapse were 30% (95% confidence inter­
val (Cl), 10-49%), 35% (95% Cl, 14-56%), and 34% 
(95% Cl, 13-55%), respectively. The projected 5-year 
probability of survival was 68% (95% Cl, 50-86%). 
Projected at 5 years, probablities of leukemia-free sur­
vival (LFS) in hematologic, cytogenetic and molecular 
remission were 55% (95% Cl, 37-73% ), 51% (95% Cl, 
32-69%), and 51% (95% Cl, 32-70%), respectively. All 
patients with relapse but one who relapsed in blastic
ability o f hematologic relapse for patients transplanted with 
an unmanipulated graft in CPI varies from 9 to 21%.1-4 
It increases to 25- for patients transplanted in more 
advanced phases. u ,-‘i T cell depletion reduces the incidence
and severity of GVHD but also increases the risk of 
r e l a p s e . T h e  probability of relapse after transplantation 
for CML-CP1 with lymphocyte-depleted
phase were treated with retransplantation (n 1) or
is 4 0 -
1 If hematologic and cytogenetic relapses are 
combined, the probability of relapse is even higher.12 How­
ever, the Ph chromosome may appear only transiently and
is not neccessarily followed by hematological relapse.1-1 1(1 
The clinical relevance of a small number of persisting cells 
expressing the BCR-ABL mRNA has been discussed by 
several authors.17 20 It has been speculated whether the 
complete disappearance of the BCR-ABL gene rearrange­
ment was necessary for cure of the disease.18,20 ~  However, 
using PCR with nested primers, a relationship was observed 
between PCR positivity and relapse.-3,24 Quantitative PCR 
in consecutive samples showed that the number of residual 
tumor cells had important prognostic value.*1-*5
For CML patients who relapse, treatment options are lim-with the infusion of lymphocytes (n = 6). Six patients 
regained second hematologic remission and five entered itecl. In patients with cytogenetic or hematological relapse, 
second cytogenetic and molecular remission. Including a - interferon significantly improved the 2-year probability
o f  survival but long-term survival did not differ from that 
in patients who were not treated with «-interferon.2<) 
Retransplantation is associated with a high treatment-
these patients, the probability of survival in first or 
second hematologic remission at the end of follow-up
was 68% (95% Cl, 50-86%). The probabilities of sur­
vival in first or second cytogenetic and molecular related morbidity and mortality. Following a second trans- 
remission at the end of follow-up were both 61% (95% plant for CML 2-y ear proba
Cl, 42-80%). We advocate revaluation of T cell val (C l) ) of treatment-related mortality, relapse and leuke-
depletion of donor marrow for patients with CML-CP1, mia-free survival were 35% (95% Cl, 20-53%), )
especially for those at high risk of developing Cl, 27-62%), and 37% (95% Cl, 23-53%), respectively.-10 
GVHD. Retransplantation may become more successful since trans-
Key words: T cell-depleted BMT; CML-CP1; LFS; plant-related mortality can be reduced by less intensive
survival in first or second complete remission as high-dose busulphan
, sever* on
treatment of relapse after bone marrow transplantation with
from the original marrow
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of
Complete remission was induced in 54 pi 
(73% ) with relapsed CML.’5
In the present analysis we report on the outcome of trans­
plantation for CML-CP1 with HLA, MLC-identical sibling
grafts depleted of lymphocytes using counterflow centrifug-
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(International Medical, Zutphen, The Netherlands) have 
been placed eccentrically in a rotor (type Mark-1; Dijkstra 
Vereenigde, Amsterdam, The Netherlands) that has been 
installed in a modification (Curame-3000) of the Varifuge- 
retransplantation (n = 1) or with the infusion of lympho- RF centrifuge (Heraeus Separationstechnic, Ostenrode,
ation. All patients received a conditioning regimen which 
was intensified by the addition of anthracyclines. In all 
patients with a relapse, except one who relapsed into blastic 
phase, we attempted to induce second remission with
cytes from the original marrow donor (/? 6).
form of immunotherapy, we observed high probabilities of 
LFS and of survival in first or second remission.
Materials and methods
Patients, donors and methods
July and August 61 consecutive
patients were transplanted for CML-CP1. Fifteen patients 
were excluded from analysis because they received marrow 
from non-HLA, MLC-identical family donors (n = 7) or
Germany). The particles in the separation chamber are sub
to two opposing forces: the centrifugal 
depending upon the rotor speed and the centripetal force 
caused by the continuous fluid stream pumped into the 
chamber with a direction towards the rotor axis. At equilib­
rium the cells are positioned according to their size with 
the larger cells in the more centrifugal position and the 
smaller cells in the more centripetal direction. By increas­
ing the centripetal force and/or decreasing the centrifugal 
force this equilibrium shifts towards the of the
chamber and the smaller cells are the first to leave the 
chamber. The rotor outlets are monitored for cell number
and size
unrelated donors (// = 8). Another eight patients 
were excluded since indication for transplantation was Ph 
chromosome and BCR/ABL breakpoint negative CML (n 
= 1) or conditioning for BMT was performed without the 
addition of anthracyclines (n = 7). Median age of the 
remaining 38 recipients (18 females and 20 males) was 37 
(range 19—54) years. The donors (14 females and 24 males) 
were aged from 17 to 71 (median 39) years.
using a cell scatter-contr
Thirty-four patients were conditioned with cyclophospham­
ide 60 mg/kg body weight/day on days - 6  and - 5  and total 
body irradiation (TBI) given in two equal fractions o f 4.5 
Gy each on days - 2  and -1  using a 16 MV or 18 MV  
photon beam linear accelerator. The conditioning regimen
device. The cells are collected in several rotor speed frac­
tions. In each fraction the number of nucleated cells is mea­
sured by using a cell counter (Coulter Counter; Coulter 
Corporation, Hialeah, FL, USA). After binding to CD3- 
FITC monoclonal antibody (Dakopatts, Glostrup, 
Denmark) the percentage of T lymphocytes is determined 
by using an Epics Elite fiowcytometer (Coulter 
Corporation). With this technique it is permitted to add a 
fixed number of T cells to each graft individually.
The marrow that was ultimately given to the recipient 
consisted of the larger cell fractions with an absolute total 
number of T lymphocytes between 0.4 and 3.2 (median 
1.1) x 10(Vkg body weight of the recipient.
was by the addition of
Imnnmoprophylaxis after transplantation  
Immunoprophylaxis post-transplant consisted of cyclospor-
(daunorubicin to a total dose of 156 mg/m2 or idarubicin ine A (CsA) alone, 3 mg/kg body weight/day by continuous
to a total dose of 42 mg/m2) by continuous intravenous 
(i.v.) infusion for 2 or 7 days.”’ Four patients were con­
ditioned without TBI. They received idarubicin to a total 
dose of 42 mg/m2 by continuous i.v. infusion on days - 1 2  
and - I I ,  busulphan 4 mg/kg/body weight (days - 8  to - 5  
inclusive) and cyclophosphamide 60 mg/kg/body weight on 
days - 3  and -2 .  Bone marrow was infused on day 0.
i.v. infusion from days -1  to +14, followed by 2 mg/kg 
body weight/day. As soon as CsA could be taken orally, it 
was given in a dose of 6 mg/kg body weight/day to 12 
weeks after BMT, followed by a gradual tapering off and 
discontinuation after 16 weeks post-grafting.
D onor marrow
Donor marrow was depleted of lymphocytes by density 
gradient centrifugation followed by counterfiow centrifug-
M anagement o f  patients
All patients were managed in single rooms with filtered air 
under positive pressure throughout the transplantation per­
iod inside the hospital, and all received oral selective gut 
decontamination, as well as co-trimoxazole lor Pneutno-
ation as described before.19-40 In summary: bone marrow is cystis carinii prophylaxis and oral acyclovir for prophylaxis
filtered through a nylon filter with a pore size o f 70 ¡im. 
After removal of plasma and fat, a mononuclear cell frac­
tion with a density <1.073 g/ml is isolated in gradients of  
Percoll (Percoll, Uppsala, Sweden). Then the low density 
mononuclear fraction is pumped into the separation 
chamber which is placed eccentrically in a centrifugation
of herpes infection.
rotor. The separation capacity o f  the original single­
chamber rotor (Beckman JE-6; Beckman, Palo Alto, CA,
has been enhanced by the development of a multi-
GVHD
The clinical manifestations of acute GVHD were graded 1 
to 4 according to the criteria described by Glucksberg et 
al . 4 I  Chronic GVHD was classified as limited or extensive 
as described by Shulman et a l:v- If GVHD occurred =S3
months retransplantation or =£3 the
;r counterfiow centrifugation system with four 
ation chambers reducing the total time of the •iati on
to about 3 h. The transparant chambers
infusion of lymphocytes it was defined as acute. If the 
patients had GVHD beyond 3 months, it was defined as 
chronic.
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Bone m arrow samples
As part of an ongoing study on chimerism, bone marrow 
samples were taken before BMT, 0.5 and 1 year after trans­
plantation and annually thereafter. From 1991 onwards, 
bone marrow samples were analyzed prospectively for the 
presence of BCR/ABL breakpoint molecules. PCR analysis 
o f  samples taken before 1991 was done retrospectively in 
liquid nitrogen stored bone marrow. If cytogenetic analysis 
for the Ph chromosome and/or PCR for the BCR/ABL  
breakpoint was positive, bone marrow samples were taken 
and analyzed at shorter intervals.
Cytogenetic analysis
For demonstration of the Ph chromosome, bone marrow 
cells were prepared directly and/or cultured for 24 h in 
RPMI 1640 medium (Gibco, Paisley, UK) without mito­
gens and processed for GTG banding.4-1 As a standard, 32 
metaphases were analyzed.
PCR analysis
Two series of PCR were performed as described before.
In summary: RNA was isolated from bone marrow cells in 
a modification of the method of Chomczynski and Sacchi.43 
Primers for the synthesis of cDNA (A 2 1 ) and for the two 
series of PCR were derived from the Sequence, 
EMBL/Genebank accession No. M 30828 (Heidelberg, 
Germany). Primers B 1 1 and A21 were used in the first 30- 
cycle series and the internal primers B12 and A22 in the 
second 35-cycle PCR. The quality o f each RNA sample 
was assessed in a reverse transcriptase reaction followed  
by PCR on j82-microglobulin RNA. Strict precautions were 
taken to avoid contaminations. In each PCR, both positive 
and negative controls were used. PCR products were ana­
lyzed by hybridization after Southern blotting using a ’-P- 
labeled c-ABL probe recognizing the 5' part of exon 2 o f  
the c-ABL gene. With this PCR, we were able to demon­
strate one K562 cell among 10s normal cells.
* . *
liions
Hematologic relapse was defined as the reappearance o f  
clinical features and laboratory findings characteristic for 
CML. Cytogenetic relapse was the recurrence o f  meta- 
phases with the Ph chromosome. A molecular relapse was 
defined as a positive PCR at two or more consecutive points 
of time after BMT.
If PCR for BCR/ABL was negative and the patient had 
no cytogenetic or hematologic relapse, he was in molecular 
remission. The patient was in cytogenetic remission if the 
bone marrow showed no Ph chromosome-positive meta-
survived in second hematologic, cytogenetic or molecular
remission if they regained hematologic, cytogenetic or mol­
ecular remission, respectively, and remained in that 
remission until the end of follow-up. For these patients fol­
low-up was calculated from T cell-depleted BMT onwards.
Take failure was defined as primary (leukocytes always 
< 1 . 0 x  1071) or as secondary (leukocytes s^l.Ox 10*71 on 
3 or more consecutive days with disappearance of leuko­
cytes in
Follow -up
Follow-up was until death or 1 August 1996. For surviving 
patients, follow-up was at least 12 months.
Trea tm ent o f  relapse
Before the era of lymphocyte infusions for the treatment of 
relapse, one patient had been retransplanted directly with 
unmanipulated marrow from the original donor. Condition­
ing for second BMT consisted of busulphan 16 mg/kg and 
cyclophosphamide (200 mg/kg). Six patients with a relapse 
were given lymphocytes from the original marrow donor
.15.44as 'C.
sties
Fisher’s exact test was used for comparison of two pro-
the Statisticamíportions. Calculations were 
Release 4.1 programme (Apple Computer, Cupertino, CA, 
USA). P  values <0.05  were considered significant. The 
probabilities of relapse, survival and LFS were calculated
the Kaplan-Meier me in pr
abilities were calculated using the log-rank test and Wil- 
coxon ’s test. Calculations were made using the SAS pro-
gramme Cary, NC, USA). P  values <0.05  
were considered significant. The Kaplan-Meier method 
was also used for the calculation of the probability of sur­
vival in first or second remission at the end of follow- 
For this calculation, patients who relapsed and attained 
second remission after retransplantation or \ 
infusion o f lymphocytes were not scored for relapse, Prob­
ability of survival in first or second remission was ealeu-
BMT onwards and was givenh from T cell-de
only for the endpoint of follow-up. Probability of survival 
in second remission was given separately for survival in 
second hematologic, cytogenetic and molecular remission.
In terva l fro m  diagnosis to transplantation
phases and the patient had no hematologic relapse. Hemato- Interval from diagnosis to transplantation varied from 3 to 
logic remission was defined as the disappearance o f  signs 62 (median 10) months. Twenty-nine patients (76%) were 
or symptoms of CML and normalization o f  blood counts transplanted «£12 months after diagnosis of CML. Four of 
and bone marrow cellularity in the absence of antileu­
kemic therapy.
ilients (14%) who were transplanted tr.rk*- 1 yeiu I
sis relapsed hematologically compared to three of 
LFS was defined as survival in first hematologic nine (33%) transplanted beyond 1 year (P >0.05). A eom-
remission. If LFS refers to survival in first cytogenetic or difference was observed for cytogenetic and mol-
lirst molecular remission this is stated in the text. Patients ecular relapse, respectively (data not shown).
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All 37 patients with a follow-up of more than 0.5 months 
engrafted. Two patients (5%) suffered from secondary take 
failure at 2 and 3 months, respectively. Both were retrans­
planted with an unmanipulated graft after conditioning with 
total lymphoid irradiation given in two fractions of 2 Gy 
on each of 3 consecutive days to a total dose of 12 Gy. 
One of these patients died from GVHD at 3 months after
retri ation. The other remi in molecular
remission at 40 months after the first BMT and 38 months 
a ft e r retransplantation.
death are given in Table 2. Only one patient died from
relapse at 50 months T cell-depleted BMT.
relapsed at 48 months in blastic phase and was treated 
symptomatically only. One patient died in molecular 
remission from overwhelming pneumococcal sepsis at 69 
months after the first BMT and 27 months after retransplan­
tation for relapse. She was not immunized with pneumococ­
cal vaccine after (re)transplantation. Cause o f death was 
Ebstein-Barr virus-associated secondary lymphoma in one 
patient. She died 17 months after T cell-depleted transplan­
tation.
GVHD
Acute GVHD occurred after T cell-depleted BMT 
before retransplantation or the infusion of lymphocytes in 
20 of 37 engrafted patients (54%). Twelve patients (32%) 
had acute GVHD grade 1, seven (19%) grade 2 and one 
patient (3%) suffered from grade 3 acute GVHD.
Chronic GVHD before retransplantation or before lym­
phocyte infusion occurred in 16 o f  33 patients (48%) with Figure 1.
a follow-up of > 3  months. GVHD was limited in 10 (30%)
and extensive in six patients (18%).
The incidence but not the severity of acute GVHD in the 
nine patients after retransplantation (n = 3) or after the
Relapse
Hematologic relapse was observed in seven patients at 12- 
48 (median 24) months after T cell-depleted BMT. In three
hematologic relapse occurred at 4 -1 2  (median 6) 
cytogenetic and at 6-23  (median 12) months 
ar relapse. The probability of hematological 
relapse was 30% (95% Cl, 10-49%) and is given in
Eight patients had a cytogenetic relapse at 6 -48  (median 
24) months after BMT. In one of these patients cytogenetic 
relapse was preceded by molecular relapse which occurred 
19 months earlier. The probability of cytogenetic relapse
infusion of lymphocytes (/? = 6) was significantly higher was 35% (95% CI, 14—56%) and is shown in Figure 1.
than that observed in these patients after T cell-depleted 
BMT (Table 1). The incidence of extensive chronic GVHD  
was significantly higher after retransplantation (n = 1) or 
after the infusion of lymphocytes (n = 6) in the seven 
patients who were evaluable for chronic GVHD after T had cytogenetic or hematologic relapse and PCR was nega-
Thirteen patients had positive PCR for the BCR/ABL 
breakpoint at 6 -4 8  (median 24) months after transplan­
tation. In five patients PCR was only positive at one time- 
point after BMT. At that time, none of these five recipients
cell-depleted BMT and after retransplantation or after lym­
phocyte infusion and this is shown in Table I.
M  o rta I i tv
Ten of 38 patients (26%) died at 0 .5-69 (median 6) months 
after lymphocyte-depleted BMT. The principal causes of
tive in two to live consecutive analyses in later follow-up. 
As given in the definitions, these patients were not con-
relapse. Molecular relapse
ian 18) months after
4  \  H i a
occurred in eight patients at 6-48  
transplantation. One patient had a molecular relapse with-
out cytogenetic or atologic relapse at the
time o f  molecular relapse. Nineteen and 23 months later he
death and the interval between T cell-depleted BMT and relapsed cytogenetically and hematologically, respectively.
Table 1 The incidence and severity ol' acute and chronic GVHD after T cell-depleted BMT and after retransplantalion or the infusion of lymphocytes
No. (%) o f  nau'ents with GVHD P vahu
No. of patients = 9
Acute GVHD 
none 
grade I
2= grade 2 
& grade 3
After T 
ceil-depleted BMT
6 (67) 
2 ( 2 2 ) 
1 ( I D  
0 ( 0 )
After ivtranspluiuation
or lymphocyte infusion
1 ( I I )  
3 (33) 
5
2 ( 22 )
0.025
NS
NS
V j
No. o f  patients = 7 
Chronic GVHD
none
limited
»  V  i  - j i m  y  i  \ m
5 (71)
2 (29) 
0 ( 0 )
1 (14)
n
4 (57) 0.035
NS = not significant.
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Table 2 Principal causes o f  death and interval between T cell-depleted BMT and death
Principal cause o f  death n
Cytomegalovirus-associated interstitial pneumonitis 
Adult respiratory distress syndrome 
Graft-versus-host disease (n = 2)
after T cell-depleted BMT
after retransplantation with an unmanipulated graft 
Secondary lymphoma 
Untreated relapse
Pneumococcal sepsis after retransplantation
10
1
1
1
1
i
1
1
" f t *
interval BMT unti 
death (in months)
1.5 and 2
6 and 6 
0.5
4
17
50
Months after T cell-depleted BMT
Figure 1 Probability of hematologic (a) and cytogenetic (b) relapse. Tick  
marks in the relapse curves denote survivors in first hematologic (a) and 
first cytogenetic (b) remission after T cell-depleted BMT. The difference 
between the probabilities of relapse was not significant.
The probability of molecular relapse was 34% (95% Cl, 
13-55%). Since the curve for the probability of molecular 
relapse is almost identical to that o f cytogenetic relapse, 
this curve is not given.
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Months after T cell-depleted BMT
Figure 2 Probability of survival. Tick marks in the survival curve indi­
cate patients who are alive. Arrows above the tick murks denote the four 
patients who are in second hematologic, cytogenetic and molecular 
remission (note: the arrow at 5 1 months marks two patients, one is in first 
remission and the other in second remission). Arrows below (he lick marks 
show the two patients who are (not yet) in second cytogenetic and molecu­
lar remission. Tick marks not indicated with an arrow show the 22 patients 
who are in first hematologic, cytogenetic and molecular remission.
Sunnval
Twenty-eight of 38 patients (74%) were alive at 12-120  
(median 51) months after BMT. Of these, seven were alive
after retransplantation for secondary take failure (/?, 1 ) o r
after the infusion of lymphocytes (n =  6). The probability 
of survival is given in Figure 2 and was 68% (95%  Cl, 
50-86%).
Probability o f  leukemia-free survival
At 12-120 (median 45) months, 23 o f  38 patients (61 %)
were alive and in first hematologic remission. Probability
of LFS was 55% (95% Cl, 37-73%) and is given in Figure 
3. Twenty-two of 38 patients (58%) were alive and in first 
cytogenetic remission at 12-120 (median 43) months after 
T cell-depleted BMT. The probability o f LFS in first cyto­
genetic remission was 51% (95% Cl, 32-69% ) and is given  
in Figure 3. At 12-120 (median 43) months, 22 o f  38 
patients (58%) were alive and in first molecular remission. 
Probability of LFS in molecular remission was 51% (95%  
Cl, 32-70%). Since the curve for LFS in molecular
1.0
0.8
0.6
203
JQ
O
u .
a. 0,4
0.2
s
0.0
o
« - f  t. . v . i  —— .*<*• • - -  I . .  „ . ,  ,i. V..  j  . . .
12 24
I i ir 
I a
1  i t  i l i
à iii ikk
a
b
—-* 1. i , ÿ f ..
36 48 60 72 84 108 120 132
Months after T cell-depleted BMT
Figure 3 Probability of leukemia-free survival is given for survival in 
first hematologic (a) and first cytogenetic (b) remission after T cell 
depeleted BMT. Tick marks in the curves denote leukemia-free survivors
The difference between the probability of leukemia-free survival was 
not significant.
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remission was almost identical to that of LFS in 
remission this curve is not shown.
relapse after transplantation for CML-CP 1 with T cell- 
depleted grafts varied from 48% at 3 years after BMT to
at 8 years post-transplant.2"4-" Several factors may 
have contributed to this relatively low incidence of hemato­
logic relapse observed in our population. Firstly, whenProbability o f  survival in first or second remission
Seven patients were treated for relapse with retransplan- counterflow centrifugation is used lor depletion o f  lympho-
tation (n =  1) or with the infusion of lymphocytes from the cyles, it retains the relatively large lymphocytes in the graft,
original marrow donor (n = 6). The patient who was given This lymphocyte population contains most o f the large
a second transplant with an unmanipulated graft for hema- granular lymphocytes which belong to the MHC nonrestric-
tologic relapse died in molecular remission from over- ted cytotoxic cells (natural killer (NK) cells) having the
whelming pneumococcal sepsis at 27 months after retrans- capability to inhibit the growth of fresh clonogenic CML
plantation. Five patients were given lymphocytes for cells.49 This suggests that NK cells are precursors or effec-
hematologic relapse and all regained hematologic remission tors of graft-versus-leukemia reaction. The phenotype of
and all but one entered second cytogenetic and molecular MHC nonrestricted cytotoxic cells is predominantly CD3" 
emission. One patientr for and CD 16 a small population bears CD3 and
genetic relapse only. At 12-120 (median 51) months after CD16.S0 These cells will also be eliminated if depletion 
T cell-depleted BMT, 28 o f 38 patients (74%) were alive techniques with monoclonal antibodies are used for lym- 
and in first or second hematologic remission. The prob- phocyte depletion. Secondly, the addition of anthracyclines 
ability of survival in first or second hematologic remission to the conditioning regimen may have decreased the prob­
at the end of follow-up and calculated from T cell-depleted ability of relapse as described earlier.-16--™ However, this 
BMT onwards was 68% (95% Cl, 50-86%). Twenty-six of appeared not to be due to the additional elimination of leu-
38 patients (68%) were alive and in cytogenetic remission 
at 12-120 (median 51) months after lymphocyte-depleted 
BMT. The probability o f survival in first or second cyto­
genetic remission at the end of follow-up from T cell- 
depleted BMT onwards was 61% (95% Cl, 42-80%). This 
probability will increase further if the two patients who still
kemic cells by anthracyclines but more to the relatively 
higher incidence o f GVHD as reported by Bär et al.5i They 
observed a lower incidence of mixed erythrocyte chimer- 
ism, a higher incidence of acute GVHD 5= grade 1 and a 
trend to a lower relapse rate in patients conditioned with 
the addition of anthracyclines. The addition of anthracy-
had Ph chromosome-positive metaphases after lymphocyte clines to the conditioning regimen may have resulted prim-
infusion enter a second cytogenetic remission. The prob- arily in an additional elimination of immunocompetent
ability o f survival in first or second molecular remission at autologous T lymphocytes tipping the immunological bal-
the end of follow-up and calculated from T cell-depleted ance towards the low number of T lymphocytes given
BMT onwards was identical to that of survival in first or within the graft. Thirdly, 29 of 38 patients (76%) were
second cytogenetic remission.
Discussion
In the present analysis, acute GVHD 3s grade 2 occurred 
in eight of 37 patients (22%). This contrasts favorably with 
results from the study for the EBMT of Ringden et a/.46
transplanted within 1 year after diagnosis of CML and this 
may be another explanation for the relatively low prob­
ability o f relapse. Patients transplanted beyond 1 year after 
diagnosis of CML tended to have a higher relapse incidence 
than patients transplanted within 1 year after diagnosis,
erences were not significant." 4
They observed acute GVHD grade 2 in 305 of 780
The probabilities o f  cytogenetic and molecular relapse 
did not differ significantly from that o f hematologic relapse. 
In all but one of the eight patients cytogenetic relapse her-
patients (39%) after first transplantation for CML-CP1 with aided or occurred simultaneously with hematologic relapse
grafts from HLA-identical siblings. In 22% of cases, grafts 
were T cell-depleted. In the same study, day 100 mortality
and molecular relapse preceded or coincided with cyto­
genetic relapse. Our policy is to treat patients only with the
for CML-CP1 patients was 17%. In contrast, only three o f infusion o f donor lymphocytes if cytogenetic relapse has 
38 patients (8%) in the present analysis had died at day 
100. The relatively low incidence of acute GVHD gn
2 in our patients is reflected in the relatively low day 100 
mortality. Seven out of 10 patients died beyond day 100. 
Nowadays, three o f these patients might have been saved 
by adoptive immunotherapy,47 an earlier diagnosis of 
impending relapse28 or by pneumococcal prophylaxis.48
The incidence of acute and the severity of chronic
at two or more consecutive occasions with 
an increasing percentage of Ph chromosome-positive meta- 
phases. Patients with a molecular relapse only are not 
treated.
transplantation for CML-CP 1 with T cell-LFS
depleted and HLA-identical sibling grafts varied from 37% 
at 2 years to 21% at 8 years after BMT.4,7,52 After transplan­
tation for CML-CP 1 with unmanipulated grafts from HLA-
GVHD after retransplantation with an un manipulated graft identical siblings, LFS varied from 44% at 8 years to 68% 
or after the infusion o f lymphocytes was higher than that at 2 years post-transplant.-1'4'52 In contrast to Goldman et at2
observed in these patients after T cell-depleted BMT. This others concluded that T cell-depletion significantly reduced
observation shows that for each patient individually the LFS.3,4 In the present analysis LFS projected at 5 years
occurrence and severity of GVHD depends on the number 
of lymphocytes infused.
The projected 5-year probability o f hematologic relapse 
in our patients was 30%. The probability o f hematologic
after BMT was 55% and is comparable with LFS obtained 
in recipients of unmanipulated marrow.
Patients who relapse from CML can be treated with 
retransplantation or preferably with the infusion of lympho-
Lymphocyte-depleted transplantation for CML-CP1
ire et al
w m
cytes from the original bone m a r ro w  d o n o r .  Inc lud ing  these 13 Cooperative Study Group on Chromosomes in T n
patients we found a high probability o f  survival in 
second remission at the end of follow-up.
We BMT for CML-
CP1 with grafts from HLA-identical sibling donors which 
are depleted of lymphocytes using counterflow centrifug-
ofation is comparable with that obtained in red 
unmanipulated grafts. Even after intensification of the con­
ditioning regimen by the addition o f  anthracyclines, prob­
ability of relapse remains higher than in recipients of 
unmanipulated grafts. However, the major advantage of T
cell-depleted transplantation remains lower mortality
caused by GVHD. The higher probability o f relapse is not 
the major drawback anymore since patients with a relapse 
can be offered a very good chance o f  attaining second
origina
'MVi
donor. For that reason we advocate a revaluation of T cell-
remission by infusion of lymphocytes from
depletion of donor marrow for patients with CML-C 
high risk of developing GVHD.
at
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